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Pathologic extraskeletal bone formation, or heterotopic ossifica-
tion (HO), occurs following mechanical trauma, burns, orthopedic
operations, and in patients with hyperactivating mutations of the
type I bone morphogenetic protein receptor ACVR1 (Activin type 1
receptor). Extraskeletal bone forms through an endochondral pro-
cess with a cartilage intermediary prompting the hypothesis that
hypoxic signaling present during cartilage formation drives HO
development and that HO precursor cells derive from a mesenchy-
mal lineage as defined by Paired related homeobox 1 (Prx). Here
we demonstrate that Hypoxia inducible factor-1α (Hif1α), a key
mediator of cellular adaptation to hypoxia, is highly expressed and
active in three separate mouse models: trauma-induced, genetic, and
a hybrid model of genetic and trauma-induced HO. In each of these
models, Hif1α expression coincides with the expression of master
transcription factor of cartilage, Sox9 [(sex determining region Y)-
box 9]. Pharmacologic inhibition of Hif1α using PX-478 or rapamycin
significantly decreased or inhibited extraskeletal bone formation.
Importantly, de novo soft-tissue HO was eliminated or significantly
diminished in treated mice. Lineage-tracing mice demonstrate that
cells forming HO belong to the Prx lineage. Burn/tenotomy per-
formed in lineage-specific Hif1α knockout mice (Prx-Cre/Hif1αfl:fl)
resulted in substantially decreased HO, and again lack of de novo
soft-tissue HO. Genetic loss of Hif1α in mesenchymal cells marked by
Prx-cre prevents the formation of the mesenchymal condensations
as shown by routine histology and immunostaining for Sox9 and
PDGFRα. Pharmacologic inhibition of Hif1α had a similar effect on
mesenchymal condensation development. Our findings indicate that
Hif1α represents a promising target to prevent and treat pathologic
extraskeletal bone.
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Heterotopic ossification (HO) is the pathologic formation ofextraskeletal bone in soft tissues. This process occurs in two
separate patient populations: those with severe trauma, including
large surface-area burns, musculoskeletal injury, orthopedic op-
erations, and even spinal cord injury; and those with a genetic
disease known as fibrodysplasia ossificans progressiva (FOP) (1–
4). FOP is caused by a hyperactivating mutation in the type I
bone morphogenetic protein (BMP) receptor ACVR1 (Activin
type 1 receptor), and patients with FOP develop ectopic bone
lesions in the absence of any substantial trauma. The clinical
sequela of these pathologic ectopic bone formations, whether in
the setting of trauma or genetic mutations, include nonhealing
wounds, chronic pain, and joint immobility. In the case of FOP,
progressive ossification may lead to death as a result of loss of
thoracic cage compliance.
Treatment options for HO are limited because bone often
recurs following surgical resection, and some patients may have
nonresectable HO because of its sensitive location. The risk of
an operation may outweigh the benefits of excision, especially in
the face of recurrence (5). Therefore, there is a need to identify
therapeutic options that can prevent HO before its initial oc-
currence in at-risk patients. Furthermore, the identification of a
common treatment strategy for patients with musculoskeletal
trauma and patients with FOP would represent a substantial
advance in our understanding of these disease processes.
Several rodent models exist to study HO in the setting of
musculoskeletal trauma or genetic mutation. In the burn/tenotomy
model, mice undergo Achilles’ tendon transection with
concomitant partial-thickness dorsal burn injury; HO forms in
this model at the tendon transection site (2, 3). To study genetic
HO, two prominent models have evolved: (i) intramuscular HO
through Ad.cre-inducible constitutively active ACVR1 (caACVR1:
ACVR1 Q207D) with cardiotoxin injection (1), and (ii) congenital
HO in conditional caACVR1 knockin mice [Nfatc1 (nuclear factor of
activated T-cells, cytoplasmic 1)-cre/caACVR1fl/wt] (6). HO in the
burn/tenotomy model and the ACVR1fl/wtmodels has been shown to
develop through a cartilaginous intermediary, suggesting that this
process occurs through endochondral ossification. Therefore, we
hypothesized that targeting development of the cartilaginous in-
termediary would be sufficient to inhibit or minimize HO formation.
Significance
Heterotopic ossification (HO) is a debilitating condition in which
bone forms inappropriately within soft tissues. Two vastly dif-
ferent patient populations are at risk for developing HO: those
with musculoskeletal trauma or severe burns and those with a
genetic mutation in the bone morphogenetic protein receptor
ACVR1 (Activin type 1 receptor). In this study, we demonstrate
that both forms of HO share a common signaling pathway
through hypoxia inducible factor-1α, and that pharmacologic in-
hibition or genetic knockout of this signaling pathway can miti-
gate and even abolish HO formation. These findings pave the
way for pharmacologic inhibitors of hypoxia inducible factor-1α
as therapeutic options for heterotopic ossification.
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Hypoxia inducible factor-1α (Hif1α) is one particular signaling
mediator that has been shown to be critical for normal chondro-
genesis (7–10). Conditional Hif1α knockout mice have demonstrated
that Hif1α is critical for chondrocyte survival and differentiation.
Given the critical role of Hif1α in normal cartilage development and
that HO forms through a cartilaginous intermediary, we hypothe-
sized that targeting Hif1α through drug treatment or conditional
Hif1α knockout would inhibit HO formation.
Results
Human Trauma Patients Exhibit Up-Regulation of HIF1α and Related
Downstream Vascular Signaling Mediators. We used a genomic da-
tabase of 244 patients at high risk for HO because of large surface-
area burns to compare with unburned “control” patients (11, 12). A
total of 25,000 genes were queried, of which 3,500 were noted to be
significantly different in tissue from burn patients compared with
control patients. A total of 25,000 genes were queried, of which
3,500 were noted to be significantly different in tissue from burn
patients compared with control patients. In particular, we noted
significant up-regulation of HIF1α, placing it within the top 50
up-regulated gene transcripts. In addition, related downstream
gene transcripts, including vWF (von Willebrand factor), PECAM
(platelet endothelial cell adhesion molecule-1), FLT1 (fms-related
tyrosine kinase 1), CDH5 (cadherin 5), and VEGF were up-regulated
(Fig. 1). In our evaluation of HIF1α, we queried the Ingenuity
Pathway Knowledgebase for HIF1α downstream genes for which
expression levels are previously known to be changed by activation
of HIF1α (13, 14). The expression level of HIF1α was significantly
up-regulated after burns [fold change = 2.103, false-discovery rate
(FDR) < 0.05] with pathway activation z-score of 4.965, placing it
within the top 50 up-regulated genes.
HO in Three Separate Animal Models Is Characterized by Elevated
Hif1α Expression. Three separate models of HO were studied:
(i) burn/tenotomy, (ii) Ad.cre/cardiotoxin-inducible caACVR1
expression, and (iii) congenital HO (Nfatc1-cre/caACVR1fl/wt)
(Fig. 2). Notably, when burn/tenotomy was performed in oxygen-
dependent degradation domain (ODD)-Luc Hif1α reporter
mice, we detected a highly positive signal at the tenotomy site
compared with the uninjured side, which indicates that the
tenotomy site becomes highly hypoxic (Fig. 3A). Immunos-
taining for Hif1α confirmed its expression in each of these
three models (Fig. 3 B–J). Importantly, Hif1α was present
during the precartilage and immature HO phases in the burn/
tenotomy model and slowly receded with the formation of
mature HO. In the burn/tenotomy model, Hif1α colocalized
with the chondrogenic marker Sox9 [(sex determining region
Y)-box 9], suggesting its intimate role in cartilage formation in
this model (Fig. 3 B–D). Within mature HO observed 9 wk
after trauma, Hif1α expression was present only within the
marrow space of the heterotopic bone, but was no longer
present within the osteoid or along the periphery of the HO
lesion (Fig. 3D).
Similarly, HO lesions that developed in the Ad.cre/cardiotoxin
model demonstrated a similar pattern of Hif1α expression with
colocalization with Sox9 and pSmad 1/5, a known regulator of
bone development (Fig. 3 E–G). Of note, inflammation is a
common feature of both models, and therefore Hif1α stabiliza-
tion is not an unexpected finding (13).
Therefore, to understand whether Hif1α plays a role in the
formation of HO in the absence of inflammatory trauma, as in
patients with hyperactive ACVR1, we used a model in which
HO develops spontaneously as a result of constitutive activity
of ACVR1 (Nfatc1-Cre/caACVR1fl:wt) (14). These mice spon-
taneously develop HO lesions within 4–5 d after birth without
Fig. 1. (A) Ingenuity pathway analysis of mRNA transcripts isolated from adipose tissue from burn or unburned “control” patients. (B) Up-regulation of the
provasculogenic pathway, including HIF1α, vWF, PECAM, FLT1, CDH5, and VEGF. (C) Numeric-fold increase in gene expression of burn patients compared with
unburned, control patients.
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concomitant trauma or Ad.Cre or cardiotoxin injections. Lesions
are generally localized to the joints, including ankles, knees, elbows,
and digits (14). Immunostaining confirmed robust Hif1α expression
within immature HO also in this model, which indicates that Hif1α
plays a role in HO formation in the setting of hyperactive BMP
receptor signaling despite absence of inflammatory trauma (Fig. 3
H–J). Again, robust colocalization of Hif1α with Sox9 and
pSmad 1/5 was noted.
Fig. 2. (A) Trauma-induced model of HO in which mice receive a 30% total body surface-area partial-thickness dorsal burn injury with hindlimb Achilles’
tendon transection, resulting in HO formation along the calcaneus as well as proximally within the soft tissue. (B) Hybrid model of HO wherein Ad.cre and
cardiotoxin are injected into the gastrocnemius muscle of caACVR1fl:flmice resulting in intramuscular HO formation. (C) Nfatc1-Cre/caACVR1fl:wtmice develop
HO generally localized to the joints 4–5 d after birth in a model of genetic HO.
Fig. 3. (A) Bioluminescent image of Hif1α reporter ODD-Luc mouse after burn/tenotomy demonstrating increased signal at the burn (yellow circle) and
tenotomy (red circle) sites. (B) Pentachrome images depicting uninjured hindlimb, and precartilage, cartilage anlagen with immature HO, and mature HO
phases. (C) Immunostaining for Hif1α in uninjured, precartilage, immature HO, and mature HO showing robust expression in the precartilage and immature
HO phases. (D) Costaining for Sox9 (green) or pSmad 1/5 (green) with Hif1α (red) in uninjured, precartilage, immature HO, and mature HO. (E) Pentachrome
image of Ad.cre/cardiotoxin showing areas of cartilage and osteoid. (F) Immunostaining for Hif1α showing robust expression. (G) Costaining of Sox9 (green)
or pSmad 1/5 (green) with Hif1α (red) in the Ad.cre/cardiotoxin model. (H) Pentachrome image of littermate control and Nfatc1-cre/caACVR1fl/fl mouse
showing cartilage presence in the mutant. (I) Immunostaining for Hif1α showing robust expression within the mutant cartilage sites. (J) Costaining of Sox9
(green) or pSmad 1/5 (green) with Hif1α (red) in the Nfatc1-cre/caACVR1fl/fl mouse. Green asterisk, tendon; purple asterisk, cartilage anlagen; yellow asterisk,
immature HO; blue asterisk, mature HO; white asterisk, native bone.
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Taken together, these data show that Hif1α expression ap-
pears to be a common denominator in trauma-induced and ge-
netic models of HO, and precedes cartilage formation and
cartilage ossification, thereby validating it as a therapeutic target.
Pharmacologic Inhibition of Hif1α Limits HO After Burn/Tenotomy.
Next, we tested the hypothesis that Hif1α inhibition can prevent
HO. For this purpose, we used the drug PX-478, which has been
shown to inhibit Hif1α transcription and translation (15). In vitro
treatment of cells derived from the tenotomy site 3 weeks after
injury (3WLST) and cultured in hypoxia showed diminished
levels of the Hif1α transcript and of the chondrogenic gene
transcripts Sox9 and Acan (aggrecan) upon treatment with PX-
478 (Fig. 4A). Additionally, PX-478 and rapamycin, a previously
described Hif1α inhibitor (16), both significantly diminished
Hif1α produced by mesenchymal cells isolated from tendon,
confirming again that these drugs affect Hif1α levels in cells local
to the future HO site (Fig. S1). We next tested whether treat-
ment with PX-478 decreases Hif1α expression and cartilage
formation in vivo, and consequently inhibits overall development
of HO. Mice received burn/tenotomy and were subsequently
treated with PX-478; histologic evaluation after 3 wk confirmed a
substantial decrease in the cartilage anlagen, which is typically
present after 3 wk (Fig. 4B). Furthermore, we found diminished
Hif1α expression 3 wk after injury (Fig. 4C). Consistent with
these data, expression of Sox9 was considerably diminished in
the PX-478–treated group (Fig. 4C). Moreover, burn/tenotomy
mice treated with PX-478 demonstrated a significant reduction
in total HO volume at 5 wk (4.3 mm3 vs. 1.5 mm3, P < 0.05) and 9
wk (5.8 mm3 vs. 2.3 mm3, P < 0.05) after injury (Fig. 4 D and E).
Finally, PX-478 treatment completely inhibited “soft tissue”
HO—extraskeletal bone, which forms within the proximal
transected tendon and distal gastrocnemius but away from the
calcaneus—after 9 wk, as shown by binary analysis (yes/no: χ2 = 9.5,
P < 0.01) and quantitative comparison (0.90 mm3 vs. 0.00 mm3,
P = 0.05) (Fig. 4E). This result is notable, as soft tissue HO
likely forms de novo without the influence of adjacent carti-
lage, bone, or periosteum normally located in close proximity to
extraskeletal bone at the calcaneus. Taken together, these findings
suggest that Hif1α is a permissive factor for chondrogenesis and its
inhibition can prevent transition of nonosteochondro progenitor
lineage cells into cells forming cartilage and ultimately extraskeletal
bone. Notably, we found no adverse effects of PX-478 on wound
healing of the burn or at the hindlimb tenotomy sites (Fig. S2). To
test a second Hif1α inhibitor, mice were treated with rapamycin
(16), resulting in significantly diminished de novo HO formation
(1.60 mm3 vs. 0.81 mm3, P < 0.05) (Fig. 4 F and G) (16).
Pharmacologic Inhibition of Hif1α Limits HO Caused by ACVR1
Constitutive Activity. We next confirmed these findings in mod-
els of constitutive ACVR1 activity caused by expression of the
caACVR1 (ACVR1 Q207D) mutation. caACVR1fl/fl mice injected
with cardiotoxin and Ad.cre develop robust HO and this model
has been used to study inhibitors of ACVR1 signaling. caACVR1fl/fl
mice treated with PX-478 demonstrated near elimination of
cartilage or bone based on pentachrome staining (Fig. 5A) after
Ad.cre/cardiotoxin induction. Similarly, there was elimination of
Hif1α and Sox9 based on immunostaining (Fig. 5B). Finally,
microCT analysis confirmed the complete absence of HO in the
PX-478 treated group based on binary analysis (yes/no; χ2 =
13.6, P < 0.001) and quantitative comparison (18.1 mm3 vs.
0.01 mm3, P = 0.01) (Fig. 5 C and D). These findings were
striking because of the substantially improved efficacy over
other BMP inhibitors in the literature. Pentachrome staining
Fig. 4. (A) In vitro treatment of soft tissue cells isolated from tendon with PX-478 (10 μM) diminishes gene transcripts of Hif1α, Sox9, and Acan in chon-
drogenic differentiation medium. (B) PX-478 treatment of burn/tenotomy mouse substantially diminishes ossification and cartilage presence compared with
control. (C) Immunostaining demonstrates substantially reduced Hif1α expression in PX-478–treated burn/tenotomy mice with concomitant reduction in Sox9
expression. (D) Three-dimensional reconstruction and serial cross-sections of microCT scans of PX-478 and control-treated burn/tenotomy mice. (E) PX-478
significantly decreases total HO volume in burn/tenotomy mice (5-wk volume: 4.3 mm3 vs. 1.5 mm3, P < 0.05; 9-wk volume: 5.8 mm3 vs. 2.3 mm3, P < 0.05; 9-wk
normalized volume: 1.0 vs. 0.4, P < 0.05) and eliminates soft tissue HO in burn/tenotomy model (9-wk volume: 0.90 mm3 vs. 0.00 mm3, P = 0.05; 9-wk nor-
malized volume: 1.0 vs. 0.0, P = 0.05; yes/no: χ2 = 9.5, P < 0.01). (F) Three-dimensional reconstruction and serial cross-sections of microCT scans of rapamycin
and control-treated burn/tenotomy mice. (G) Rapamycin treatment significantly reduces de novo HO formation (9-wk volume: 1.60 mm3 vs. 0.81 mm3, P <
0.05; 9-wk normalized volume: 1.0 vs. 0.51, P < 0.05). *P < 0.05 for volumetric measurements; †P < 0.05 for binary analysis (yes/no); red circle, soft tissue
heterotopic bone; yellow circle, calcaneal heterotopic bone; n = 3 for PX-478–treated mice; n = 11 for PX-478 control mice; n = 5 for rapamycin-treated mice;
n = 4 for rapamycin control mice.
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confirmed absence of cartilage and bone (Fig. 5C) and
immunostaining further confirmed absence of Hif1α and
Sox9 expression (Fig. 5D). Again, these findings were repli-
cated using rapamycin which showed complete absence of HO
in treated mice (17.5 mm3 vs. 0.0 mm3, P < 0.001; yes/no; χ2 =
14.3, P < 0.001) (Fig. 5 E and F).
Finally, PX-478 was administered to mice with congenital HO
(Nfatc1-cre/caACVR1fl/fl) every other day starting from birth for
2 wk. Treated mice had significantly less ectopic bone at the
ankle joints compared with mutant mice treated with vehicle
(6.8 mm3 vs. 2.2 mm3, P < 0.01) (Fig. 5 G and H).
Genetic Loss of in Mesenchymal Progenitors Prevents Formation of
Heterotopic Ossifications. To strengthen our findings, we next used
a conditional Hif1α knockout mouse because global Hif1α
knockout is embryonic lethal. We first established that hetero-
topic ossification following burn/tenotomy consists of cells from
the paired related homeobox (Prx)-lineage using a series of lineage
tracing experiments with Prx-cre/ROSA26mTmG mice (Fig. 6). Impor-
tantly, we found that HO which formed within the soft tissue and
more proximally within the soft tissue both exhibited nearly
100% presence of Prx-cre cells. In fact, we noted that the only
non–Prx-cre cells present were those forming the marrow space
of the mature HO.
We therefore used a mouse model of conditional Hif1α knock-
out in Prx-cre cells (Prx-cre/Hif1αfl/fl). These mice have been shown
to exhibit defective normal cartilage development (7). However,
the impact on pathologic heterotopic ossification has not been
demonstrated; therefore, burn/tenotomy was performed in Prx-cre/
Hif1αfl/fl mice. Mutant mice developed minimal HO only around
the calcaneus, and even these lesions were substantially smaller
than in controls (5.02 mm3 vs. 0.18 mm3, P < 0.01) (Fig. 7 A and B).
Fig. 5. (A) Pentachrome stain of Ad.cre/cardiotoxin-induced caACVR1fl/fl mouse treated with PX-478. (B) Absence of Hif1α or Sox9 expression after PX-478
treatment. (C) Three-dimensional reconstructions and cross-sections of microCT scans of PX-478 and control-treated hybrid model mice. (D) PX-478–treated
hybrid model mice produced almost no evidence of HO on microCT compared with control-treated mice (control: n = 12 legs, PX-478: n = 12 legs) (volume:
18.1 mm3 vs. 0.01 mm3, P = 0.01; normalized volume: 1.0 vs. 0.0, P = 0.01; yes/no: χ2 = 13.6, P < 0.001). (E) Three-dimensional reconstructions and cross-sections
of microCT scans of rapamycin and control-treated hybrid model mice. (F) Rapamycin-treated hybrid model mice produced no evidence of HO on microCT
compared with control-treated mice (control: n = 8 legs, rapamycin: n = 10 legs) (volume: 17.5 mm3 vs. 0.00 mm3, P < 0.001; normalized volume: 1.0 vs. 0.0, P <
0.05; yes/no: χ2 = 14.3, P < 0.001). (G) Ankle reconstructions of control and PX-478–treated genetic HO mice. (H) Ankle extraskeletal bone volume quanti-
fication of genetic HO mice treated with control or PX-478 (800 Hounsfield units) (volume: 6.8 mm3 vs. 2.2 mm3, P < 0.01; normalized volume: 1.0 vs. 0.32, P <
0.01; n = 4 control treated legs; n = 4 PX-478–treated legs). *P < 0.05 for volumetric measurements; †P < 0.05 for binary analysis (yes/no); red circle, het-
erotopic bone.
Fig. 6. (A) Longitudinal section of Prx-cre/ROSAmTmG mouse hindlimb
showing areas of Prx-cre cells (green). (B) Axial sections showing tendon and
muscle of Prx-cre/ROSAmTmG showing evidence of Prx-cre cells in tendon and
connective tissue of muscle, but not within the myocytes. (C) Axial sections
of precartilage and mature HO in Prx-cre/ROSAmTmG showing that Prx-cre
cells form the majority of HO.
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Additionally, we noted that soft tissue HO was nearly completely
abolished in mutant mice, consistent with our findings using
PX-478 treatment based on volume (0.32 mm3 vs. 0.01 mm3) and
binary analysis (yes/no; χ2 = 3.7, P = 0.05) (Fig. 7B).
Recognizing that the conditional Hif1α knockout mouse used
in this study demonstrates growth plate abnormalities, we first
evaluated the uninjured Achilles’ tendon and tibia. The un-
injured mutant tendon cross-sectional area was 60% of the
littermate control, whereas the uninjured mutant tibial length
was 32% of the littermate control. Importantly, the histologic
appearance of the tendon appeared normal, as did the tibial
cortex (Fig. 7C). Because of these differences in phenotype, we
normalized HO values to either cross-sectional tendon area or
tibial length (Fig. 7D). As expected, the differences remained
significant because of the nearly complete absence of HO in the
mutant model.
On histologic evaluation with serial pentachrome stains, we
were unable to identify any regions of heterotopic ossification,
either near the calcaneus or within the soft tissue (Fig. 7E).
Therefore, histologic evaluation showed no evidence of cartilage
presence, and nearly complete absence of Hif1α (Fig. 7F) and
only minimal expression of Sox9 or pSmad 1/5 in mutant mice
(Fig. 7G). These findings indicate that genetic loss of Hif1α in
mesenchymal progenitor cells is sufficient to prevent formation
of extraskeletal bone.
Loss of Hif1α Prevents Formation of Mesenchymal Condensations
in HO Models. Next, we sought to understand why inhibiting
Hif1α impairs HO formation. Therefore, the HO mesenchyme of
conditional Hif1α knockout mice and littermate controls was
evaluated 3 wk after burn/tenotomy injury. Routine histologic
evaluation using H&E demonstrated absence of a mesenchymal
condensation in the knockout mouse. Furthermore immunostaining
for PDGFRα, a previously described marker of mesenchymal
cells within mesenchymal condensations (17–19), and Sox9
confirmed the absence of mesenchymal condensation (Fig. 8 A–C).
Similar to Hif1α knockout, PX-478 and rapamycin treatment
substantially diminished the presence of mesenchymal progenitor
cells and the formation of mesenchymal condensation as shown
by H&E staining, as well as PDGFRα and Sox9 immunostain-
ing (Fig. 8). We then searched for PDGFRα+/Sox9+ cells in
sites outside of the developing HO including the tendon-
calcaneal insertion site of the uninjured hindlimb of treated or un-
treated mice, and Cre-conditional Hif1α knockout mice (Fig. S3).
To confirm the effect of Hif1α inhibition on the Ad.cre/cardiotoxin
model similar staining was performed for PDGFRα/Sox9+ cells.
Again, we found a significantly diminished number of these
cells in the setting of treatment 2 wk after induction (Fig. S4 A
and B). To demonstrate a decrease in mesenchymal progenitor
cells after early injury, we performed analyzed sections from the
Ad.cre/cardiotoxin model 5 d after injury with similar results
(Fig. S4C).
Discussion
HO is a pathologic process in two separate patient populations:
those with severe burns and musculoskeletal trauma, and those
with genetic mutations in the ACVR1 gene conferring hyperac-
tivity. To date, emphasis has been placed on the treatment of
Fig. 7. (A) Serial microCT cross-sections showing Prx-Cre/Hif1αfl:fl mice make minimal total HO after burn/tenotomy and no soft tissue HO. (B) Prx-Cre/Hif1αfl:fl
mice produce significantly less total HO (9-wk volume: 5.02 mm3 vs. 0.18 mm3, P < 0.01; 9-wk normalized volume: 1.0 vs. 0.03, P < 0.01) and soft tissue HO
(9-wk volume: 0.32 mm3 vs. 0.01 mm3; 9-wk normalized volume: 1.0 vs. 0.0; yes/no: χ2 = 3.7, P < 0.05) compared with littermate controls. (C) Histologic image
of representative tendon cross-sections in mutant and littermate control mice. (D) Total HO normalized to tibial length (total HO normalized to tibial length:
1.0 vs. 0.11, P < 0.05) or tendon cross-sectional area (total HO normalized to tendon cross-sectional area: 1.0 vs. 0.04, P < 0.05) and soft tissue HO normalized
to tibial length (soft tissue HO normalized to tibial length: 1.0 vs. 0.0; yes/no: P < 0.05) or tendon cross-sectional area (soft tissue HO normalized to tendon
cross-sectional area: 1.0 vs. 0.0; yes/no: P < 0.05). (E) Serial pentachrome images of Prx-Cre/Hif1αfl:fl 9 wk after burn/tenotomy confirming absence of ossi-
fication with minimal cartilage formation. (F) Absence of Hif1α expression after burn/tenotomy in mutant mice. (G) Corresponding absence of Sox9 (green)
and pSmad 1/5 (green) expression after burn/tenotomy in mutant mice. *P < 0.05 for volumetric measurements; †P < 0.05 for binary analysis (yes/no); red
circle, heterotopic bone; green asterisk, tendon; purple asterisk, cartilage anlagen; yellow asterisk, immature HO; n = 4 mutants; n = 3 littermate controls.
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patients with the ACVR1 mutation, and a common signaling
mediator between the two forms of HO has not been evaluated
for therapeutic efficacy. Here, we leverage our knowledge of
endochondral ossification to demonstrate that Hif1α represents
a common target for both forms of ectopic bone formation.
Genetic loss or pharmacologic inhibition of Hif1α significantly
and consistently reduce or eliminate HO. Our findings are
consistent in a model of trauma-induced HO with burn/tenotomy,
and in two different models of genetic HO: one in which the
constitutively active ACVR1 gene is activated with exogenous
Ad.cre injection and cardiotoxin to stimulate inflammation
(caACVR1fl/fl), and a second nontrauma model in which the
constitutively active ACVR1 gene is conditionally expressed
from birth (Nfatc1-cre/caACVR1fl/fl). These findings suggest
that targeting the early phase of HO development—cartilage
formation—represents a common solution to a pathology
with several varying etiologies.
Transcriptome analysis shows significant up-regulation of
Hif1α in adipose tissue isolated from burn patients. Mesenchy-
mal cells with the capacity for osteogenic differentiation and
which may serve as HO progenitor cells reside within adipose
tissues, making this an appropriate tissue type to assay. Addi-
tionally, burn patients are a critical patient population at risk for
trauma-induced HO development (2, 3, 20). Our recent analysis
has shown that patients with burn total body surface area
(TBSA) > 30% have 23-times higher odds of developing HO
compared with patients with smaller surface-area burns, vali-
dating use of this cohort of patients with >20% TBSA burns for
transcriptome analysis (21). Ingenuity pathway analysis showed
that the Hif1α signaling pathway is up-regulated in the adipose
tissues of burn patients, indicating downstream consequences.
Although Hif1α is one of the top 50 transcription factors up-
regulated in response to burn injury, other factors are also up-
regulated. However, these initial findings prompted our interest
in further evaluating Hif1α as it is highly expressed in response to
trauma in tissues with mesenchymal cells capable of osteogenic
differentiation, and is critical for cartilage development.
Histologic characterization of HO has established that,
whether in the setting of trauma or mutated ACVR1, this pro-
cess occurs through endochondral ossification. Endochondral
ossification is characterized by the initial presence of mesen-
chymal cells, which condense and likely differentiate to form a
cartilage template. Numerous studies have demonstrated that
hypoxia induces chondrogenesis of mesenchymal cells, sug-
gesting a prominent role for Hif1α. Additional data indicate
that conditional loss of Hif1α within mesenchymal cells delays
mesenchymal cell differentiation into chondrocytes (7).
Along these lines, in the setting of trauma-induced HO, the
first step is a fibroproliferative stage that mimics the condensa-
tion event occurring during development. Both genetic loss
of Hif1α in mesenchymal cells and pharmacologic inhibition of
Hif1α severely impairs HO formation by preventing formation of
mesenchymal condensations. In the model of conditional Hif1α
knockout in Prx-cre cells, we found minimal HO formation with
almost no mesenchymal condensations or cartilage formation.
Previous gene knockdown efforts using siRNA suggest that
Hif1α is important but are unable to account for the cells in
which Hif1α signaling is critical. The paired related homeobox
(Prx or Prrx1) lineage has previously been shown to mark the
lateral plate mesoderm and limb bud mesenchyme (22). Using
Prx-cre/ROSA26mTmG mice, we showed that the Prx-cre+ cells
form HO throughout development from early chondrogenesis to
late ossification. We therefore used this lineage to evaluate how
genetic loss of Hif1α in this lineage affects HO using Prx-cre/
Hif1αfl/fl mice. The absence of chondrogenesis following burn/
tenotomy is consistent with studies demonstrating impaired
growth plate formation in these mice. Based on the published data
however, the complete absence of mesenchymal condensations
Fig. 8. (A) Absence of mesenchymal condensation based on H&E staining of Hif1α knockout mutant and diminished mesenchymal condensation in rapa-
mycin- or PX-478–treated burn/tenotomy mice compared with control 3 wk after injury. (B) Absence of PDGFRα immunostaining in Hif1α knockout mutant
and diminished PDGFRα immunostaining in rapamycin- or PX-478–treated burn/tenotomy mice compared with control 3 wk after injury. (C) Absence of Sox9
immunostaining in Hif1α knockout mutant and diminished Sox9 immunostaining in rapamycin- or PX-478–treated burn/tenotomy mice compared with
control 3 wk after injury. (D) Absence of PDGFRα+/Sox9+ cells in Hif1α knockout mutant and diminished PDGFRα+/Sox9+ cells in rapamycin- or PX-478–treated
burn/tenotomy mice compared with control 3 wk after injury. (E) Quantification of mesenchymal progenitor cells (PDGFRα+) and condensing mesenchymal
cells (PDGFRα+/Sox9+) cells. Yellow dotted line outlines tendon; red dotted line outlines mesenchymal condensation. *P < 0.05. (Magnification: 20×.)
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at the tendon transection site was unexpected but striking (7–9).
Additionally, gene knockout reduced the number of mesenchy-
mal progenitor cells, as determined by expression of PDGFRα.
Treatment or gene knockout did not alter the presence of
condensing mesenchymal cells in uninjured sites (e.g., tendon-
calcaneal insertion or enthesis), as these cells are not present in
the absence of injury. To confirm the absence of the mesenchymal
condensations, we performed routine histologic evaluation with
H&E in addition to immunostaining for PDGFRα (17–19) and
Sox9 (7). Both PDGFRα and Sox9 have been previously described
as markers of the developing mesenchyme, whereas H&E can
also been used to identify the mesenchymal condensation (23).
In this study, we used two different drugs, PX-478 and rapa-
mycin, to inhibit Hif1α (15, 16, 24–29). PX-478 has been shown
to decrease Hif1α both in vitro and in vivo by decreasing Hif1α
mRNA levels and blocking Hif1α mRNA translation (27, 30, 31).
Constitutive VEGF signaling abrogates the effect of PX-478 on
downstream angiogenic signaling, confirming that its effect is
upstream of VEGF. Furthermore, the effect of PX-478 is limited
to hypoxia, as angiogenic signaling is not altered in the presence
of PX-478 under normoxic conditions (28). PX-478 does not
appear to alter retinoic acid signaling, a pathway previously
shown to affect HO formation (32). Separately, we used rapa-
mycin, which inhibits Hif1α through the mammalian target of
rapamycin (mTOR) (16, 33). When we tested these drugs in vitro
on mesenchymal cells isolated from the tendon and cultured in
hypoxia, we observed a significant decrease in Hif1α. Although
both PX-478 and rapamycin may have off-target effects, their
shared effect on Hif1α along with results from our conditional
Hif1α knockout mouse indicate that pharmacologic inhibition of
Hif1α is a viable therapeutic strategy to prevent HO. Similar to
the effect of genetic loss, pharmacologic inhibition of Hif1α
significantly diminished or eliminated de novo heterotopic bone,
and diminished the number of mesenchymal progenitor cells and
mesenchymal condensations.
Strikingly, in the setting of ACVR1 mutation, pharmacologic
Hif1α inhibition with PX-478 or rapamycin again prevents HO
formation. This finding suggests that constitutive ACVR1 ac-
tivity alone is not sufficient to induce HO, and is consistent with
our clinical knowledge that patients with fibrodysplasia ossificans
progressiva who have a hyperactivating mutation in ACVR1
(ACVR1 R206H) develop ectopic bone lesions following minor
trauma (4). Similar to the burn/tenotomy model, we found that
mesenchymal cells marked by coexpression of PDGFRα and
Sox9 were present in the developing lesion of untreated mice,
but eliminated in the setting of therapeutic Hif1α inhibition. The
effect of PX-478 on heterotopic bone in the Nfatc1-cre model is
consistent with the role of Hif1α in cartilage maintenance, as
previously reported (9, 12). To our knowledge, for the first time a
common target has been demonstrated between trauma-induced
and genetic HO that is consistent with the developmental role of
Hif1α in endochondral ossification. These findings also suggest
that pharmacologic agents with Hif1α inhibitory potential, such
as PX-478 or rapamycin, may serve as therapeutic options even
for HO caused by hyperactive ACVR1 signaling. Previously,
siRNA directed against Hif1α has been shown to decrease HO
formation in a burn/tenotomy model (34). Our study develops
these preliminary findings by demonstrating that available
pharmacologic agents deserve attention for inhibitory potential
in patients. siRNA currently lacks therapeutic efficacy in patients
with heterotopic ossification, prompting the need for therapeutic
options such as PX-478 or rapamycin. It is nearly impossible to
determine the exact anatomic location where HO will form,
making it difficult to precisely deliver local treatments. This
challenge associated with local delivery can be obviated with
systemic delivery of pharmacologic options. However, we ac-
knowledge that further studies must be performed to determine
the optimal dosing and timing of administration of these drugs.
Our findings suggest a new paradigm for treatment of heterotopic
ossifications that targets Hif1α. We found that pharmacotherapy
with Hif1α inhibitors, such as rapamycin or PX-478, can potently
diminish extraskeletal bone formation in different models of HO.
This effect appears to be related to diminution or absence of
mesenchymal condensations which precede HO formation.
Methods
Ethics Statement. All animal experiments described were approved by the
University Committee on Use and Care of Animals at the University of
Michigan, Ann Arbor (Protocols: #05909, 05182, and 05716). This study was
carried out in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health
(35). All animal procedures were carried out in accordance with the guide-
lines provided in the Guide for the Use and Care of Laboratory Animals:
Eighth Edition from the Institute for Laboratory Animal Research (35). In-
stitutional review board approval was obtained through the University of
Michigan (HUM051190), University of Texas Medical Branch, University of
Florida, and Massachusetts General Hospital.
Patient Enrollment and Sampling for Gene-Expression Profiling. Written
consent was obtained for all human studies. Institutional review board ap-
proval was obtained through the University of Texas Medical Branch. Patient
enrollment and sample collection for patients have been described pre-
viously (36). Between 2000 and 2009, 244 burn patients were enrolled at one
of four burn centers if admission occurred within 96 h postinjury, at least
20% of the TBSA was affected, and at least one excision and grafting pro-
cedure was required. Additionally, 35 healthy control subjects (16–55 y) were
recruited between 2004 and 2007. In both the burn patients and the control
patients, adipose tissue was collected and analyzed for RNA transcript levels.
Using a fine scissor or scalpel, 80 mg of adipose tissue was obtained and
immediately placed on an iced Petri dish and cut into a 2- to 5-mm cube. The
sample was placed in a cryogenic tube containing 2 mL RNAlater to stabilize
the tissue according to standard operating procedure B001.03, and the tis-
sue was processed to total cellular RNA using a commercial RNA purification
kit (RNeasy, Qiagen) according to standard operating procedure G026.01.
Biotinylated cRNA was generated from 4 μg of total cellular RNA, hybridized
onto HU133 Plus 2.0 GeneChips, stained, and washed according to the
manufacturer’s recommendations. A total of 25,000 genes were queried, of
which 3,500 were significantly changed with an FDR < 0.001 and defined
fold-change ≥ 1.5.
Analysis of Time-Course Gene-Expression Data. Specimens were immediately
stabilized using RNAlater (Ambion). Total cellular RNA was extracted from
the remaining specimens with good quality using a commercial RNA puri-
fication kit (RNeasy, Qiagen). Biotinylated cRNA was generated from 1 μg of
total cellular RNA using the 3′ IVT Express Kit and protocol of Affymetrix,
and hybridized onto an HU133 Plus 2.0 GeneChip (Affymetrix). EDGE (Ex-
traction of Differential Gene Expression) was used to estimate the signifi-
cance of expression changes for each gene by 1,000 random permutations.
Significant genes were selected by FDR < 0.001 and fold-change ≥ 1.5. These
genes were further analyzed using ingenuity pathway analysis (37).
Animals. Mice included for extraskeletal bone evaluation were wild-type
C57BL/6 (Charles River Laboratory), Cdh5-Cre/tdTomatofl/wt, Prx-Cre/Hif1αfl/fl,
Prx-Cre/ROSA26mTmG, caAcvr1fl/fl, Nfatc1-Cre/caAcvr1fl/wt, or littermate con-
trols. All breeding was performed at the University of Michigan in facilities
managed by the Unit for Laboratory Animal Medicine at the University of
Michigan. Tail genomic DNA was used for genotyping. Mice used for bio-
luminescent imaging were homozygous for the ODD-luc transgene. In these
mice, the C-terminal portion of the hip1α ODD is fused to the firefly lucif-
erase (luc) gene. Hypoxia causes stabilization of the fusion protein thereby
increasing fluorescence upon luciferin administration.
Extraskeletal Bone Models. All mice received presurgical analgesia consisting
of 0.1 mg/kg buprenorphine, followed by anesthesia with inhaled isoflurane,
and close postoperative monitoring with analgesic administration.
Burn/tenotomy mice received a 30% TBSA partial-thickness burn on the
shaved dorsum followed by left hindlimb Achilles’ tendon transection. The
dorsum was burned using a metal block heated to 60 °C in a water bath and
applied to the dorsum for 18 s continuously. The tenotomy site was closed
with a single 5-0 vicryl stitch placed through the skin only.
caAcvr1fl:fl mice received hindlimb cardiotoxin and Ad.cre injection at post-
natal day 24. Mice were then killed after 22 d (PX-478) or 15 d (rapamycin).
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Separate controls were used for each drug treatment to account for dif-
ferences in the day of killing.
Nfatc1-Cre/caAcvr1fl:wt mice were generated by crossing Nfatc1-Cre+ mice
with caAcvr1fl:wt mice. Resulting mutants developed extraskeletal bone by
postnatal day 4–5.
Drug Treatment. Burn/tenotomy or hybrid HOmice were administered PX-478
(100 mg/kg) or rapamycin (5 mg/kg) in PBS solution via intraperitoneal in-
jection.Mice received injections every other day for the duration of the study.
Nfatc1-Cre/caACVR1fl:wt mice were administered PX-478 (100 mg/kg) every
other day for a total of 2 wk.
Isolation and Culture of Mesenchymal Stem Cells. Mouse mesenchymal stem
cells were harvested from the tendon transection site originating from the
calcaneus to the confluence of the fibula and tibia in wild-typemice. All tissue
was mechanically minced and digested with collagenase A and dispase, and
subsequently plated. To test drug treatment on Hif1α expression, cells were
cultured in a hypoxia chamber with 0.5% oxygen. Cell treatment with PX-
478 (10 μM) or rapamycin (5 μM) was initiated 24 h before hypoxia treat-
ment and redosed in hypoxia for 24 h. Protein was harvested and analyzed
using Western blot for Hif1α and α-tubulin. To test effect of PX-478 treat-
ment on chondrogenesis, cells isolated from the tendon were cultured in
chondrogenic differentiation medium (PT-3925 and PT-4121; Lonza). All in
vitro experiments were performed in biologic and technical triplicate.
Histology and Immunofluorescence. Histologic evaluation was performed at
indicated time points in burn/tenotomy, Ad.cre/cardiotoxin, or Nfatc1-Cre/ca-
Acvr1fl:wt mutants. Hind limbs were fixed in formalin overnight at 4 °C and
subsequently decalcified in 19% (mass/vol) EDTA solution for 3–5 wk at 4 °C
until X-ray verification of decalcification. Hind limbs were paraffin- or cryo-
embedded, and 5- to 7-μm sections were cut and mounted on Superfrost
plus slides (Fisher) and stored at room temperature. H&E and Movat’s pen-
tachrome staining were performed of the ankle region. Immunostaining
staining of extraskeletal ectopic bone was performed on rehydrated wax
sections with the following primary antibodies: mouse anti-mouse anti-Hif1α
(Santa Cruz, Cat No. 53546), goat anti-mouse anti-Cdh5 (Santa Cruz, Cat No.
6458), goat anti-mouse anti-pSmad 1/5 (Santa Cruz, Cat No. 12353), goat
anti-mouse anti-CD31 (Santa Cruz, Cat No. 1506), rabbit anti-mouse anti-
Sox9 (Santa Cruz, Cat No. 20095), or anti-mouse PDGFRα. Appropriate dilu-
tions were determined before achieving final images. The appropriate
fluorescent secondary antibody was applied and visualized using fluorescent
microscopy. Secondary antibodies consisted of anti-rabbit or anti-goat
Alexafluor-488 (green) or -594 (red). All mouse sections were taken 3 wk
after burn/tenotomy. All counts were performed by blinded observer with
15 high-power fields for each sample.
Fluorescent and Bioluminescent Imaging. All fluorescent and bioluminescent
imaging was acquired using a PerkinElmer IVIS Spectrum system. Wild-type
C57BL/6 mice were used for fluorescent imaging to assess vascular perfusion.
Mice were administered Angiosense 750 EX via tail vein injection. Fluorescent
imaging was acquired 24 h after injection at 770-nm wavelength. ODD-luc
were used for all bioluminescent imaging. Mice received luciferin in-
traperitoneal injection ten minutes before imaging.
Quantitative PCR. Tissue was harvested from the tenotomy site of burn/
tenotomy mice, or from the corresponding contralateral, control hindlimb at
indicated time points. RNA was collected from tissue using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s specifications. Reverse transcrip-
tion was performed with 1 μg RNA using Taqman Reverse Transcription
Reagents (Applied Biosystems). Quantitative real-time PCR was carried out
using the Applied Biosystems Prism 7900HT Sequence Detection System and
Sybr Green PCR Master Mix (Applied Biosystems). Specific primers for these
genes were chosen based on their PrimerBank sequence (Table S1).
MicroCT and Nano-CT Analysis. MicroCT scans (Siemens Inveon using 80-kVp,
80-mA, and1,100-msexposure)wereused toquantify extraskeletalbonegrowth
in burn/tenotomy, Ad.cre/cardiotoxin, or mutant Nfatc1-cre/caAcvr1fl:wt mice.
Burn/tenotomy mice received scans at 5 and 9 wk after tenotomy. Ad.cre/car-
diotoxin mice received microCT scans at day 22 after induction with Ad.cre and
cardiotoxin injection. Nfatc1-cre/caAcvr1fl:wt mice and littermate controls re-
ceived microCT scansat day 13 after birth. Images were reconstructed and HO
volume quantified using a calibrated imaging protocol as previously described
with the MicroView microCT viewer (Parallax Innovations).
Microscopy. All fluorescently stained images were taken using an Olympus
BX-51 upright light microscope equipped with standard DAPI, 488 nm, and
TRITC cubes attached to an Olympus DP-70 high-resolution digital camera.
Each site was imaged in all channels and overlaid in DPViewer before ex-
amination in Adobe Photoshop.
Statistical Analysis. A power analysis was first performed to determine how
manymicewere needed for our PX-478 treatment groups. For power analysis,
the primary outcome of interest is differences in HO volume with treatment.
To confirm a 50% decrease in HO volume with power of 0.8, assuming an SD
of 1.5 mm3 and mean HO volume of 7.5 mm3 in untreated mice, we required
three mice per group. Means and SDs were calculated from numerical data,
as presented in the text, figures, and figure legends. In figures, bar graphs
represent means, whereas error bars represent one SD. Statistical analysis
was performed using an appropriate analysis of variance when more than
two groups were compared, followed by a post hoc Student’s t test (with a
Bonferroni correction) to directly compare two groups. Inequality of SDs was
excluded by using the Levene’s test. Outliers were excluded using the
Grubb’s test for outliers. P values are included in the figure legends.
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Fig. S1. PX-478 and rapamycin significantly decrease Hif1α protein production by mesenchymal cells isolated from uninjured tendon when cultured in hypoxia
(n = 3 biological replicates for each treatment).
Fig. S2. Comparable healing of burn site and leg incision in PX-478– and control-treated burn/tenotomy mice 10 d after injury.
Fig. S3. Absence of PDGFRα+/Sox9+ cells in the contralateral, uninjured tendon-calcaneal insertion (enthesis) of untreated, PX-478– or rapamycin-treated, or
Cre-conditional Hif1α knockout mice. (Magnification: 20×.)
Agarwal et al. www.pnas.org/cgi/content/short/1515397113 1 of 2
Fig. S4. Decreased mesenchymal progenitor cells and mesenchymal condensations in treated Ad.cre/cardiotoxin model. (A) Decreased PDGFRα+/Sox9+ con-
densing mesenchymal cells in PX-478– or rapamycin-treated mice 15 d after injury. (B) Quantification of PDGFRα+ and PDGFRα+/Sox9+ cells in untreated, or PX-
478– or rapamycin-treated mice 15 d after injury. (C) Decreased PDGFRα+ mesenchymal progenitor cells in PX-478– or rapamycin-treated mice 5 d after injury.
*P < 0.05. (Magnification: 20×.)
Table S1. Quantitative PCR primers
Species Name Accession no. Primers (5′-3′)
Mouse Hif1α NM_176958 F-GTCCCAGCTACGAAGTTACAGC
R-CAGTGCAGGATACACAAGGTTT
Sox9 NM_011448 F-AGTACCCGCATCTGCACAAC
R-ACGAAGGGTCTCTTCTCGCT
Acan NM_007424 F-ACTGCGACATCTGGAGTGAC
R-CTGTCCACTGCCAAAGAGAA
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